Enlight-LN: A Prospective Observational Registry of Patients Treated with Voclosporin for Lupus Nephritis in the United States (NKF-SCM 2023) - Feb 18, 2023 - Abstract #310; Location: Exhibit Hall; P=N/A | "The Phase 3 AURORA 1 study has shown that adding voclosporin to mycophenolate mofetil (MMF) and low-dose steroids led to earlier reductions in proteinuria across biopsy classes, races, and ethnicities, with long-term safety demonstrated over three years in patients who continued treatment in the AURORA 2 study. Twenty-four sites specialize in rheumatology, thirteen in nephrology, and two have other specialties. The study is actively enrolling patients (NCT05337124)."
Clinical • Observational data • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease • Rheumatology
|
|
Keely Da'Lee1; Keith Tagoe1; Victoria Bal1; Ron Flauto1
|